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Abstract: At least 10% of adults and virtually all children progressing to renal replacement therapy 
suffer from inherited kidney diseases. These patients rarely die when their disease progresses but 
remain alive for many years, thanks to progress in organ replacement therapy. However, these 
disorders have a large negative impact on the quality of life of the patients and on health care systems. 
Since the kidney regulates essential homeostatic processes, inherited kidney disorders have multi-
systemic complications which add to the typical challenges of rare disorders. In this review, we will 
discuss the specific nature of rare inherited kidney diseases, the challenges they are posing to the 
society, and the opportunities arising from technologic advances, which are particularly well suited to 
the kidney as a target organ. Mechanistic insights into rare disorders are relevant for common 
conditions such as hypertension, kidney stones, cardiovascular disease, and progression of chronic 
kidney disease in general. 
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Summary 
 
At least 10% of adults and virtually all children progressing to renal replacement therapy suffer 
from inherited kidney diseases. These patients rarely die when their disease progresses but remain alive 
for many years, thanks to progress in organ replacement therapy. However, these disorders have a large 
negative impact on the quality of life of the patients and on health care systems. Since the kidney 
regulates essential homeostatic processes, inherited kidney disorders have multi-systemic complications 
which add to the typical challenges of rare disorders. In this review, we will discuss the specific nature of 
rare inherited kidney diseases, the challenges they are posing to the society, and the opportunities 
arising from technologic advances, which are particularly well suited to the kidney as a target organ. 
Mechanistic insights into rare disorders are relevant for common conditions such as hypertension, 
kidney stones, cardiovascular disease, and progression of chronic kidney disease in general.  
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Introduction  
The definition of rare diseases varies around the globe: whereas any disease that affects less 
than 200,000 persons (e.g. less than 1 in 1,250) is considered 'rare' in the USA, the term is reserved for 
life-threatening or chronically debilitating diseases affecting fewer than 1 in 2,000 people in Europe,1 less 
than 1 in 2,500 people in Japan,2 and less than 1 in 500,000 people in China.3 Rare diseases, often 
qualified as "orphan" diseases to stress their severity, lack of resources and knowledge, and specific 
conditions for developing or making available drugs, represent a group of 6,000 to 8,000 disorders 
characterised by a broad diversity of clinical and biological manifestations. They are affecting an 
estimated 30 million patients in Europe.1 Approximately 80% of rare diseases have an identified genetic 
origin.4 The incidence of a given rare disease may vary substantially between regions or ethnic groups. 
For instance, congenital nephrotic syndrome of the Finnish type occurs more frequently in Finland (with 
an incidence of 1 in 8,200) than in other parts of the world.   
Rare kidney diseases represent a group of at least 150 different disorders with an overall 
prevalence of about 60-80 cases per 100,000 total population in Europe and the US.5-7 At least 10% of 
adults and virtually all children progressing to renal replacement therapy suffer from inherited kidney 
diseases, which represent the fifth most common cause of ESRD after diabetes, hypertension, 
glomerulonephritis, and pyelonephritis, respectively. In contrast to many other rare diseases, patients 
with inherited kidney disorders rarely die when their disease progresses but - thanks to progress in renal 
replacement therapy - may remain alive for many years. This apparent advantage is counterbalanced by 
severely compromised health with poor quality of life of the patients and their families. This is 
exemplified by children born with severe congenital nephropathies, who nowadays can be dialyzed from 
neonatal age onwards and thus face many decades of life with end-stage renal disease (ESRD) with a 
high likelihood of altered physical, cognitive and psychosocial development. Since the kidney regulates 
essential homeostatic processes, inherited kidney disorders have multi-systemic complications which 
add to the typical challenges of rare disorders, i.e. highly variable phenotypes, fragmented clinical and 
biological data collections, lack of standardization of diagnostic procedures and, consecutively, limited 
knowledge of disease mechanism(s) and natural history.8  
 In this review, we will first discuss the epidemiology, variety and specific nature of rare inherited 
kidney diseases of genetic origin (rare cancers and infections will not be addressed here) and the 
challenges they are posing to the society at large. We will next address the opportunities that arise from 
recent technologic advances and high-throughput screening approaches, which are particularly well 
suited to the kidney as a target organ. We will highlight the link between these technologies and 
innovative clinical research programs in rare renal diseases and initiatives funded by the European Union 
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and professional societies, and encouraged by patient organizations and support groups. We will 
illustrate how these collaborative studies may impact on the clinical management of rare kidney diseases 
and beyond - as their understanding provides key insights into other rare and common disorders such as 
hypertension, kidney stones, cardiovascular disease, effect of gender and ageing, and progression of 
chronic kidney disease.   
 
1. Rare inherited kidney diseases: why they are different  
 The kidney is characterized by a complex structural organization involving a variety of specialized 
cell types performing biological functions that are essential for homeostasis. Each kidney contains 
approximately one million functional units, the nephrons, which include a filtrating body, the 
glomerulus, followed by a tubular structure made of specific segments. These tubules converge into 
collecting ducts, which open into the renal pelvis. The physiology principles that sustain the central role 
played by the kidney have been recently reviewed.9 The kidneys are exposed to and influence the milieu 
intérieur unlike any other organ, regulating NaCl, potassium, phosphorus, calcium, magnesium and water 
balance, acid-base homeostasis, oxygen sensing and tissue oxygen supply, hormone and vitamin 
metabolism, as well as innate and adaptive immunity. The renal tissue also plays an important role in 
metabolic clearance and secretion of metabolic waste and drug metabolites. These highly regulated 
functions sustain large quantitative effects and make the body composition very sensitive to changes in 
kidney function. Primary kidney disorders can thus show a large variety of manifestations and have a 
significant impact on blood pressure, plasma composition, electrolyte and acid-base homeostasis, 
cardiac excitability, growth dynamics and puberty, and central nervous/cognitive functions. It is also 
increasingly recognized that various aspects of renal function may be affected in numerous extra-renal 
rare disorders or polymalformative syndromes (e.g. cystic fibrosis, Charcot-Marie-Tooth, Donnai-Barrow 
syndrome).10-12 The high metabolic demand of the tubular cells (in particular, those lining the proximal 
tubules) explain why the kidney is frequently involved in mitochondrial cytopathies.13  
 Genetics emerged in nephrology in the 1980s, when development of linkage analysis and 
positional cloning allowed to map the gene location of the most common form of polycystic kidney 
disease (ADPKD, in 1985),14 and identify the first mutation responsible for a monogenic kidney disorder 
(Alport syndrome, in 1990).15 This was followed (Table 1) by identification of genes involved in a series of 
classic tubular and glomerular disorders such as nephrogenic diabetes insipidus,16 Liddle syndrome,17 
Dent disease,18 Bartter and Gitelman syndromes,19,20 renal Fanconi syndrome due to nephropathic 
cystinosis,21 and steroid-resistant nephrotic syndrome.22 The identification of the molecular basis of 
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these disorders was critical to define essential mechanisms that had been predicted by earlier 
physiological and pharmacological approaches.  
 With the generalization of high-throughput and next-generation sequencing technologies, an 
increasing number of clinically-defined renal disorders have been found to have a genetic basis. As of 
today, the genetic basis of more than 160 rare kidney diseases has been defined (Table 2). These 
disorders are caused by mutations in a large variety of genes coding for proteins sustaining the 
development and complex functions of the kidney. These proteins include receptors, channels, 
exchangers, co-transporters, enzymes, transcription factors and structural components that may also 
play a role in extra-renal organs (bone, eye, brain, ...). A functional classification of rare inherited 
disorders primarily affecting the glomerulus and the tubular segments is given in Figure 1. Standardized 
analyses based on urine samples are helpful in determining the origin of these disorders.  
 Apart from the increasing number of monogenic diseases linked to clinically defined entities, the 
genetics of kidney diseases is also characterized by the cohabitation of single-gene and polygenic 
disorders. The combination of variants in the same genes or in genes involved in common pathways may 
cause a spectrum of effect sizes that cannot be explained by conventional genotype-phenotype 
correlations.9,23 Furthermore, identification of rare, recessively inherited kidney disorders combined with 
robust phenotype analysis has substantiated the biological impact of carrier states. A case in point is 
Gitelman syndrome, caused by loss-of-function mutations in SLC12A3, encoding the thiazide-sensitive 
sodium-chloride cotransporter NCC in the distal convoluted tubule. While the prevalence of Gitelman 
syndrome is 20 per million, 1% of the general population are heterozygous carriers of SLC12A3 
mutations. The carrier state for rare inactivating mutations in SLC12A3 and other genes involved in NaCl 
transport is associated with lower blood pressure and a reduced risk of hypertension,24 illustrating the 
relevance of genes involved in rare kidney disorders for more common disorders such as hypertension, 
kidney stones, and progression of CKD. 
 
2. Specific challenges 
 
2.1. Unknown genetic cause 
Despite considerable progress in understanding the genetic and molecular causes of rare kidney 
diseases, the majority of nephropathies with a genetic etiology still awaits identification. For instance, 
abnormalities in approximately 20 genes have been identified as monogenic causes of glomerulopathies, 
around 40 genes have been associated with specific tubulopathies, and 7 genes with atypical hemolytic 
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uremic syndrome (aHUS). These explain only 30-40% of familial steroid resistant nephrotic syndrome 
(SRNS), 40-50% of congenital tubulopathy, and 50-60% of aHUS cases. The actual rates of patients in 
whom a genetic diagnosis is ascertained in clinical practice are probably much lower since genetic 
screening is often not or incompletely performed. This is mainly due to the high cost and long 
turnaround times of conventional genetic screening, the common preconception that establishing a 
genetic diagnosis will not impact clinical management, and significant differences in terms of 
accessibility to genetic testing among countries in Europe.25  
 
2.2. Limited biomarkers 
 Apart from the current limitations of genetic diagnostics, there is a lack of non-invasive 
diagnostic tools and prognostic biomarkers in rare kidney disease. Despite intense research efforts into 
renal biomarkers, the assessment of kidney disease activity and progression risk is still mainly based 
upon crude markers such as serum creatinine and global proteinuria. Autoantibodies represent 
diagnostic markers for certain autoimmune nephropathies such as membranous nephropathy, aHUS and 
membranoproliferative glomerulonephritis (MPGN), but a major fraction of cases is still unexplained and 
the predictive value of autoantibodies is limited. The descriptive assessment of kidney biopsy specimens 
by light and electron microscopy, supplemented by a small set of immunological marker proteins, is still 
considered the diagnostic gold standard.26  
 
2.3. Disease heterogeneity 
An increasing number of rare kidney diseases hitherto considered single entities are found to be 
etiologically heterogeneous. Different genetic and non-genetic abnormalities may affect the same 
biological pathways and give rise to similar clinical, biochemical and histopathological features. The 
limited prognostic value of traditional diagnostic nomenclatures is largely explained by their inability to 
differentiate underlying disease mechanisms. E.g., MPGN can be caused by glomerular deposition of 
circulating immunoglobulins or immune complexes, by mutations in complement proteins regulating the 
C3 convertase, and by acquired autoantibodies directed against these proteins or C3 itself. Another 
example of similar heterogeneity is the renal Fanconi syndrome, defined as a generalized dysfunction of 
the proximal tubule.27 Since the conventional histopathological classification does not adequately 
account for these different etiologies, disease prognosis and responses to specific therapeutic 
approaches are poorly predicted by traditional disease categories. Novel disease ontologies based on 
genetic and molecular pathophysiology are only beginning to emerge and will require careful prognostic 
validation by correlating molecular phenotypes with treatment responses and long-term outcomes.  
 Considerable phenotypic variability is frequently observed among patients with monogenic 
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kidney disorders. These phenotypic differences can be the consequence of genetic (locus) heterogeneity, 
as been found for instance in Bartter syndrome (Table 2) in which the severe antenatal form of the 
disease is specifically associated with mutations in SLC12A2 or KCNJ1, whereas the classical, milder form 
is caused by mutations in CLCNKB.28 In addition, the position or nature of mutation(s) within a specific 
disease gene may influence phenotype; e.g. two truncating mutations in PKHD1 always cause a lethal 
form of autosomal recessive polycystic kidney disease (ARPKD), whereas the presence of at least one 
missense mutation can be compatible with life.29 For the majority of rare inherited kidney diseases, 
however, such genotype-phenotype correlations are absent due to their low incidence and the difficulty 
of collecting sufficiently large populations.  
Not all clinical variability is imposed by locus or allelic heterogeneity.  Indeed, within families 
affected by the exact same mutation clinical expression may vary considerably, suggesting effects of 
modifier genes, epigenetic or other modifying factors.  Gender may modify the phenotype as has been 
shown in Gitelman syndrome.30 Oligogenic modifier effects are suggested to play a role in genetic ciliary 
diseases, such as nephronophthisis; in patients with homozygous NPHP1 deletions, the presence of an 
additional heterozygous NPHP6 or NPHP8 mutation might cause additional eye or cerebellar 
involvement.31,32 With the exception of these few examples, the search for genetic and epigenetic 
modifiers in rare inherited kidney diseases has been disappointing to date.   
 
2.4. Model organisms 
 Knockout and transgenic mouse models are highly informative for in vivo demonstration of the 
effects of genetic variation on renal phenotypes.33 However, mouse models have multiple limitations 
including strain effects, adaptation, and differences from humans regarding development, growth, 
physiology, metabolism and adaptation to CKD.34,35 Furthermore, the long generation times of mouse 
models limit their use for rapid phenotyping of multiple candidate renal disease genes in the era of next 
generation sequencing.36 Because of these limitations, we are far from having ideal mouse models for 
most of the inherited kidney disorders, and using the currently available rodent models for developing 
and testing potential new drugs for human disease is often challenging. 
 
3. Opportunities 
3.1. Omics technologies 
 Recent progress in -Omics technologies has opened an unprecedented window of opportunity in 
rare renal disease research. Kidney diseases appear particularly suited to high-throughput approaches 
due to the opportunity to examine molecular events in the diseased organ (Figure 2). Kidney biopsy 
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provides the opportunity to study intrarenal biological processes ex vivo using transcriptomic and 
proteomic approaches. Tissue microdissection allows compartment-specific array and sequencing based 
profiling of mRNA transcripts as well as of non-coding regulatory RNA species. The European Renal cDNA 
Bank project (ERCB) has worked out compartment-specific gene expression profiles in a large number of 
microdissected kidney specimens from patients with various renal disorders as well as healthy subjects, 
which are available as a reference database.37 Furthermore, urine is a readily available non-invasive 
bioresource to study biochemical traits and molecular readouts directly derived from the organ of 
interest.  Amniotic fluid, which reflects at least in part renal function of the foetus, is available prenatally 
for studies in the context of renal development or transport defects.38 Exosome isolation from urine and 
amniotic fluid allows to study biomaterials containing membrane and cytoplasmatic proteins, mNRAs, 
and miRNAs that derive from every epithelial cell type facing the urinary space. Exosome analysis may be 
particularly useful for disease processes involving the renal tubule, such as lysosomal storage diseases 
and transporter mutations.39  
 The possibility to apply -omics approaches to such samples should facilitate the identification of 
molecular signatures and prognostic biomarkers, as suggested by recent studies in more common kidney 
disorders. Studies of the urine peptidome have identified molecular signatures or individual biomarkers 
for diabetic nephropathy,40 allograft rejection,41 and vesicoureteric reflux.42  Specific alterations of 
urinary miRNA expression have been detected in lupus nephritis and allograft rejection,43,44 and. 
individual miRNAs in urinary exosomes have been associated with renal disease activity.45 With a rapidly 
growing number of miRNAs being identified to be involved in disease-associated dysregulation of renal 
cell types,46 urinary exosome miRNA analysis may have significant clinical diagnostic potential. 
The study of the urine metabolome by NMR spectroscopy and mass spectrometry is another 
powerful emerging technology to generate molecular ‘fingerprints’ of diagnostic or prognostic value.47 
Initial applications of urine metabolomics in rare kidney disease demonstrated reliable differentiation of 
three different genetic forms of renal Fanconi syndrome.48  
 
3.2. Next generation sequencing  
 The perhaps most striking advances are currently being made in the field of molecular genetics. 
Next generation sequencing (NGS) techniques hold great promise for improving the diagnostic efficiency 
of rare genetic renal diseases.49-51 NGS allows simultaneous investigation of all disease genes relevant in 
the context of a given phenotype, at much reduced cost and turn-around times. Successful application of 
NGS in diagnostic mutation screening, using disease-specific multi-gene panels, has already been shown 
for several rare genetic renal disorders with locus heterogeneity, such as Alport syndrome, steroid-
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resistant nephrotic syndrome, and nephronophthisis.52-54 Beyond the disease-specific NGS panels, exome 
sequencing and potentially even whole genome sequencing will soon become part of routine molecular 
diagnostics and are expected to further improve the diagnostic yield.  
 While recent technological progress summarized above has created opportunities to generate 
unprecedented amounts of genetic and molecular information, the sheer data abundance poses an 
important new challenge in rare kidney disease research. Bioinformatic capacities and analysis tools 
need to be developed, and the functional characterization of candidate disease genes and of the 
pathogenicity of individual mutations requires efficient model systems.  
 
3.3. Model organisms 
 Despite their limitations, mice continue to represent the major model organism for rare kidney 
disorders. This has been facilitated by development of cell and time-specific gene-targeting tools and 
RNA-based technologies to manipulate gene function in vivo, and by international consortia for targeted 
embryonic stem cell clones and large scale N-ethyl-N-nitrosourea (ENU) or gene trapping mutagenesis 
programs.33 In parallel, the precision and number of phenotypic traits that can be tested has dramatically 
increased,35,55,56 and coordinated mouse phenome projects have been implemented.57 Recent advances 
in rat genetics and genome editing, combined with the excellent phenotypic analyses available in over 
500 inbred rat strains pave the way for using the rat as an alternative model organism for human 
diseases.58-60  
 In contrast to mice, simple model organisms provide opportunities for higher-throughput gene 
manipulation and phenotype quantification. Over the last decade, the zebrafish (Danio rerio) has 
emerged as an applicable system for the study of kidney diseases and renal regeneration, based on 
conserved genomic organization and nephron structure and cell types.61 While Zebrafish larvae are 
ideally suited for analysis of genes involved in kidney developmental disorders and ciliopathies,62 their 
use has recently been extended to glomerular disorders,63,64 and tubulopathies.65 The Xenopus 
pronephros has also been validated as a model of nephron segmentation, with conservation of genes 
underlying rare kidney disorders.66  
 Recent studies have shown that the fly (Drosophila melanogaster) nephrocyte combines 
filtration with protein reabsorption and can serve as a simplified model for both the podocytes and the 
cells lining the renal proximal tubule. For instance, the specialized filtration diaphragm of the nephrocyte 
is lost in flies lacking the nephrin orthologue, corresponding to the functional loss of nephrin (encoded 
by NPHS1) in human congenital nephrotic syndrome of the Finnish type.67 Furthermore, the Drosophila 
orthologs of mammalian cubilin and amnionless (AMN), two major receptors for protein reabsorption in 
the proximal tubule, function for protein uptake and maintenance of nephrocyte ultrastructure.68 
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Although the nematode model C. elegans does not possess an excretory system comparable with the 
mammalian kidney, conserved kidney disease genes play a role in this organism, including proteins 
involved in the primary cilium, kidney filtration barrier or vasopressin response.69,70  
 
3.4. EU programs, cohorts, biorepositories 
 A major obstacle to rare disease research is the fragmentation of patient-related information. To 
overcome this issue, the European Union is supporting the development of disease specific information 
networks, registries, databases and biorepositories (Table 3). Transnational registries are crucial to 
achieve sufficient sample sizes for epidemiological and clinical research. The European Platform for Rare 
Disease Registries (EPIRARE) analyzes existing rare disease registries in Europe and provides tools to 
develop a legal basis and define minimal common data elements and quality standards to allow 
information exchange between individual registries. The PARENT project will provide researchers with 
guidelines and tools to support setting-up, management and governance of interoperable patient 
registries. With even greater ambition, the RD-CONNECT platform was recently launched to integrate 
European rare disease research projects devoted to NGS and high-throughput approaches. RD-CONNECT 
is closely linked to the International Rare Diseases Research Consortium (IRDiRC) which was launched in 
April 2011 to achieve two main objectives: to deliver 200 new therapies for rare diseases and the means 
to diagnose most rare diseases by the year 2020. One of the first clinical research projects partnering 
with RD-CONNECT is EURenOmics, a consortium for -Omics research in rare kidney diseases. 
EURenOmics integrates registries and biobanks with detailed phenotype information and biomaterials 
from more than 13,000 patients to identify new genes, molecular signatures and biomarkers and work 
towards innovative therapies in patients with rare glomerulopathies, tubulopathies, complement 
disorders and renal malformations.  
 Professional and scientific societies are also increasingly involved in fostering rare kidney disease 
research. ERA-EDTA, the European association of nephrologists has implemented a working group on 
inherited kidney diseases (WGIKD) to encourage research, to promote improved and affordable care, 
and to facilitate the dissemination of knowledge to health care providers, patients and their families.71   
At the local institution level, integrated centers of competence are being established throughout 
Europe to comply with the EU Commission’s request for National Action plans for rare diseases. These 
will improve high-level health care access and, by the implementation of dedicated transition clinics, 
facilitate the move of patients with complex, life-long diseases from pediatric to adult care.72  
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3.5. Non-rare inherited kidney disorders 
 Rare kidney diseases cohabit with ADPKD, one of the most common inherited disorder with a 
prevalence of 1:1,000 (an estimated 750,000 patients in Europe). Due to the autosomal dominant 
transmission and slow progression of disease, ADPKD patients represent a very significant pressure 
group among the much smaller cohorts of patients affected by other inherited kidney diseases. The 
significant prevalence of ADPKD has impacted on the structure of research funding and drug 
development and, increasingly, on the structure and clustering of patient organizations. Potential 
treatments of ADPKD have now been tested in sufficiently powered randomized clinical trials.73  
 
3.6. Opportunities for common diseases 
 The study of rare kidney diseases may provide important insights relevant to more common 
diseases. A recent example is provided by the UMOD gene, whose dominantly inherited mutations cause 
familial juvenile hyperuricemic nephropathy.74 Genome-wide association studies (GWAS) subsequently 
showed that common variants in the UMOD promoter are strongly associated with the risk of chronic 
kidney disease and hypertension in the general population.75 Further studies revealed that these risk 
variants increase the transcriptional activity of UMOD, and that the UMOD gene product uromodulin 
interacts with the tubular cotransporter NKCC2 to cause salt sensitivity and hypertension.76 The 
elucidation of this fundamental molecular mechanism was facilitated by the previous functional 
characterization of NKCC2 as part of the exploration of Bartter’s syndrome.20 Likewise, variants in the 
genes encoding the megalin (LRP2) and cubilin (CUBN) receptors or their regulators (DAB2), which are 
essential for the tubular reuptake of ultrafiltered proteins and defective in some rare diseases, have 
been identified by GWAS to impact on renal function and the risk of CKD.77,78 Conversely, GWAS 
performed to identify common genetic variants predisposing to specific phenotypes may incidentally 
point to candidate genes for rare genetic diseases. For example, the identification of CNNM2 as the 
causative gene for a rare genetic form of severe renal magnesium wasting was based, among others, on 
a GWAS showing an association between common variants in CNNM2 and serum Mg2+ concentrations.79  
 
4. Perspectives   
 
4.1.Diagnostics 
 The rapidly growing use of NGS for clinical diagnostic purposes is expected to increase diagnostic 
efficiency in rare monogenic renal diseases. Consequently, accurate genetic counseling as well as 
possibilities for carrier testing will become available for a growing number of families and allow early 
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prenatal  or preimplantation diagnostic tests to be performed in severe cases.  In some rare renal 
diseases a definite genetic diagnosis may also have important prognostic value. For instance, the efficacy 
of plasmapheresis and outcome of renal transplantation in aHUS is correlated with the type of 
complement aberration. Patients with mutations in complement genes encoding circulating proteins 
(CFH, CFI)  have a worse outcome than patients with mutations in MCP, encoding a cell-associated 
protein.80 Likewise, in children with steroid resistant nephrotic syndrome genetic testing helps predicting 
the response to immunosuppressive therapies and the risk of post-transplant disease recurrence.81  
 
4.2. Treatment 
 The elucidation of disease mechanisms has promoted efficient therapeutic approaches for some 
rare kidney diseases (Table 2). In others, molecular therapies may be closer than anticipated (Figure 3).  
 Cystinosis is a lysosomal storage disease caused by mutations in the CTNS gene resulting in 
intralysosomal accumulation of cystine crystals causing damage in multiple organs including the kidney.21 
The oral administration of cysteamine, which reverses the intralyosomal accumulation of cystine, has 
been central to the treatment of cystinosis since the 1980's (Figure 3). When started early in life, long-
term cysteamine therapy significantly delays progression to end-stage renal disease, hypothyroidism, 
diabetes, and neuromuscular disorders.82 However, cysteamine does not replace cystinosin, does not 
prevent the proximal tubulopathy associated with the disease, and is a bothersome life-long treatment 
with significant side effects. Recent reports of syngeneic bone marrow cell (BMC) and haematopoietic 
stem cell (HSC) gene therapy as a successful treatment in a mouse model of cystinosis with reduction of 
cystine content and attenuation of the kidney injury, raise hope that BMC or HSC transplantation may 
become a potential treatment for cystinosis and other renal tubular disorders.83  
The elucidation of molecular disease mechanisms may create further opportunities to utilize 
drugs developed for other purposes in corresponding renal conditions. For instance, proteinuria recurs 
after kidney transplantation in some patients with focal-segmental glomerulosclerosis (FSGS), frequently 
leading to graft loss.84 In some of these cases, proteinuria is linked to a dysfunction of glomerular 
podocytes which involves upregulation of B7-1, a costimulatory molecule normally expressed in T-
lymphocytes, with consequent impairment of the foot process anchoring ß1-integrin proteins.85 The B7-
1 inhibitor Abatacept, approved for the treatment of rheumatoid arthritis, has recently been shown to 
induce remission of proteinuria in both post-transplant and primary FSGS.86 Other rare glomerulopathies 
also involving the inactivation of podocyte integrins might also benefit from this new indication for a 
drug designed to treat theumatological diseases.  
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  Monoclonal antibodies have recently demonstrated remarkable efficacy in several (ultra)rare 
renal disease groups. Thanks to their highly specific mechanisms of action, these compounds are ideally 
suited for targeted therapeutic approaches with minimal side effects.   
Rituximab, a B-lymphocyte depleting monoclonal antibody originally developed for the treatment of B-
cell lymphoma, has become a useful, albeit still off-label, therapy for rare immunological conditions such 
as systemic lupus erythematosus,87 autoimmune vasculitis,88 and primary glomerulonephritis refractory 
to standard treatment.89,90 The use of rituximab promises to improve disease control and minimize 
exposure to conventional, more toxic immunosuppressive drugs.   
Eculizumab is a highly potent inhibitor of the terminal complement cascade (Figure 3) which was first 
approved for the treatment of paroxysmal nocturnal hemoglobinuria, a rare acquired hematological 
disorder. Atypical hemolytic uremic syndrome (aHUS) is an ultrarare disease caused by genetic 
abnormalities in proteins regularing the alternative complement pathway. Excessive complement 
activation leads to endothelial damage and thrombotic microangiopathy in the microvasculature of the 
kidneys but also other organs including the brain. Mortality is high and survivors tend to progress rapidly  
to end-stage renal disease, with up to 100% post-transplant recurrence rate.91 Administration of 
Eculizumab induced complete disease remission in nearly all treated patients with remarkable recovery 
of renal function even after extended end-stage renal failure, turning a dismal disease into a 
permanently treatable condition.92 Its highy selective mechanism of action and apparently excellent 
benefit-risk ratio makes Eculizumab an attractive target also for other complement-mediated diseases, 
including antibody-mediated allograft rejection and membranoproliferative glomerulonephritis.92   
 The majority of AVPR2 mutations in X-linked Nephrogenic Diabetes Insipidus (NDI) and all AQP2 
mutations in autosomal recessive NDI result in normal protein that is retained within the endoplasmic 
reticulum. Agents that restore plasma routing are under investigation as potential treatments (Figure 3). 
Promising agents for X-linked NDI are cell-permeable AVPR2 antagonists or agonists that in vitro rescue 
the intracellular retention of mutant AVPR2.93-95 The therapeutic feasibility of these so-called 
pharmacologic "chaperones" has been tested in vivo. In individuals with missense AVPR2 mutations, a 
non-peptide V1a receptor antagonist showed beneficial effects on urine volume and osmolality within 
hours of administration.96 Whilst the long-term efficacy of this drug could not be tested since its clinical 
development was discontinued due to cytochrome P450 interaction, other pharmacologic chaperones in 
NDI await further in vivo testing. The chaperone approach may also become attractive for other genetic 
kidney diseases where point mutations lead to defective folding and cellular trafficking of otherwise 
intact membrane proteins (e.g. uromodulin-associated kidney diseases). Progress in this field will 
depend on the development of high-throughput compound screening compatible in vitro and in vivo 
model systems reproducing mutations in individual renal cell types.    
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4.3. Health policies 
 The global activities orchestrated by IRDiRC are aimed to stimulate scientific exploration and 
provision of competent clinical care to patients affected by rare diseases worldwide. While being made a 
public health priority, rare disease research is expected to have important repercussions on public health 
policies. Measures to translate research insights into clinical benefit include implementation of centers 
of competence for patients with rare disease with adequate diagnostic and therapeutic capabilities, 
systematic genetic counselling of affected families, early detection of relevant disorders by global or 
targeted public screening programs, and facilitated regulatory authority approval of novel orphan 
drugs.97   
Also, insights from rare diseases research may be used to modify establish public health 
measures by identifying subsets of patients at particular risk for adverse effects. For instance, a study of 
children with idiopathic hypercalciuria identified mutations in the vitamin D metabolizing enzyme 
CYP24A1 as the underlying pathology.98 Subsequently, mutations in this gene were also detected in 
patients who developed severe hypercalcemia following prophylactic bolus vitamin D administration, 
thereby identifying a subset of individuals intolerant to this generally advocated public health measure. 
 The role of patient organizations in supporting both clinical and basic research and closing the 
gap between increased mechanistic understanding and treatment for rare diseases is increasingly 
recognized.99,100 Patients want to understand their disease. They are most often keen to team up with 
physicians and researchers to give ideas, share personal insights, provide biological samples, contact 
family members and promote and participate in clinical trials. Patient organizations foster these activities 
and provide support to the physician-researcher-patient-family community. Examples in the field of rare 
kidney disorders include associations for cystic kidney disorders, oxalosis and primary hyperoxaluria, 
cystinosis, Lowe syndrome, metabolic disorders, etc. Coalitions of patient organizations are now 
significant actors in national health policies. A coalition of patient organizations proved instrumental in 
working with the US Congress to pass the Orphan Drug Act in 1983, opening a new era for the 
development of orphan drugs. The foundation for the National Organisations of Rare Disorders (NORD), 
whose operations include funding research, lobbying for legislation to benefit the rare diseases 
community, spreading information, and helping individuals with rare diseases afford medication and 
treatment. In Europe, the foundation of Orphanet, a multi-lingual reference portal for information on 
rare diseases and orphan drugs, and EURORDIS,  an alliance of more than 500 patient organisations 
active in the field of rare diseases, were major steps towards patient empowerment (Table 3). These 
organisations participate in the establishment of the European research agenda and in the work of the 
European Medicines Agency (EMA) and committees dealing with orphan drugs.  
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Figure Legends: 
 
Figure 1. Inherited kidney disorders linked to nephron segments.  
Segmental distribution of rare inherited kidney diseases (cystic and developmental disorders are not 
included). Inset, structure of the glomerulus (PEC, parietal epithelial cells; BS, Bowman space; TP, tubular 
pole; Pod, podocyte; VP, vascular pole; *, capillary lumen). 
 
Figure 2. Application of -omics technologies in rare kidney diseases.  
Genomic studies and molecular profiling of kidney tissues, plain and exosome enriched urine, together 
with multiscalar bioinformatic analysis of critical disease pathways, will facilitate the development of 
mechanistic renal disease ontologies, diagnostic tests, biomarkers and novel therapeutic targets. 
 
Figure 3. Exemples of molecular targets in rare inherited kidney diseases. 
a. Cysteamine for nephropathic cystinosis. Cystinosis is caused by mutations or deletions in the CTNS 
gene that encodes cystinosin, a ubiquitous lysosomal proton-driven cystine transporter. Cystinosin acts 
as a H+-driven lysosomal cystine transporter working in parallel with the vacuolar H+-ATPase which 
acidifies the lysosome. The influx of H+ in the lysosome drives the cystinosin-mediated transport of 
cystine from the lysosome to the cytosol. The cationic amino acid exporter PQLC2 plays an important 
role in cysteamine therapy of cystinosin. In healthy subjects, cystinosin and PQLC2 export cystine (the 
oxidized form of cysteine) and cationic amino acids, respectively, from the lysosomal lumen. Their 
activity is stimulated by the acidification of the lysosome lumen. In patients with cystinosis, the loss of 
function of cystinosin causes accumulation of cystine in the lysosomes. The drug cysteamine reduces the 
accumulation of cysteine accumulation by entering lysosomes and reacting with cystine to form a 
cysteamine-cysteine mixed disulfide, which resembles lysine. The mixed disulfide is then exported by 
PQLC2, thus depleting cystine from lysosomes and alleviating symptoms.  Modified from Jézégou A, 
Llinares E, Anne C, et al. Heptahelical protein PQLC2 is a lysosomal cationic amino acid exporter 
underlying the action of cysteamine in cystinosis therapy. Proc Natl Acad Sci U S A 2012; 109: E3434-43. 
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b. Nephrogenic diabetes insipidus (NDI). In the principal cells lining the collecting ducts, stimulation of 
the vasopressin V2 receptor by the antiduretic hormone arginine vasopressin leads to an increase in 
cAMP, causing a protein kinase A-mediated phosphorylation of the water channels AQP2 and their 
subsequent insertion in the apical plasma membrane. The resulting increase in transcellular water 
permeability is essential to mediate urine concentration. The majority of mutations in AVPR2 (X-linked 
NDI) and AQP2 (autosomal recessive NDI) results in misfolded V2R and AQP2 mutants in the 
endoplasmic reticulum (ER, Class II mutations). Pharmacological chaperones can rescue such class II 
mutants from the ER. Cell-permeable V2R antagonists stabilize the structure of mutant V2R and allow 
them to exit the ER, mature in the Golgi, and subsequently translocate to the basolateral plasma 
membrane. At the membrane, vasopressin will displace the antagonist and will allow restoration of the 
cAMP cascade. V2R agonists function similarly and may also stimulate misfolded V2R in the ER without 
inducing maturation. Mutant AQP2 can be rescued from the ER by glycerol. Modified from Wesche D, 
Deen PM, Knoers NV. Congenital nephrogenic diabetes insipidus: the current state of affairs. Pediatr 
Nephrol 2012; 27: 2183-204. 
 
c. Complement activation in atypical hemolytic uremic syndrome (aHUS). Patients with aHUS present a 
uncontrolled complement activation due to deficiency of natural complement regulatory factors (factors 
H, I and MCP), leading to membrane attack complex (C5b-9), activation of platelets, endothelial cell 
damage and systemic thrombotic microangiopathy. Eculizumab is a humanized monoclonal antibody 
that specifically inhibits the cleavage of the complement protein C5, thus blocking the activation of the 
complement system and the complement-mediated thrombotic microangiopathy in aHUS. Modified 
from Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement 
activation. Nat Rev Nephrol 2012; 8: 622-33. 
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Table 1. Milestones in inherited kidney diseases.  
Milestones in genetics : 
* 1985: Mapping the first gene location for an inherited kidney disorder (autosomal dominant polycystic 
kidney disease, on chromosome 16) - Reeders ST et al. Nature 1985; 317: 542-4. 
* 1990: First detection of a point mutation at a specific locus single-gene disorder, COL4A5 – Barker DF et 
al. Science. 1990;248: 1224-7. 
* 1992: Molecular basis of nephrogenic diabetes insipidus - Rosenthal W, et al. Nature. 1992 ;359:233-5. 
 
* 1994: Liddle syndrome due to activating mutation of the sodium channel ENaC - Shimkets RA et al. Cell. 
1994;79:407-14. 
* 1996: Molecular basis of Bartter and Gitelman syndromes - Simon DB, et al. Nat Genet. 1996;12:24-30. 
Simon DB et al. Nat Genet. 1996;13:183-8. 
* 1996: Molecular basis for inherited kidney stone diseases - Lloyd SE et al. Nature. 1996;379:445-9. 
* 1997: First nephronophthisis gene - Hildebrandt F et al. Nat Genet. 1997;17:149-53. 
* 1998: Mutations in factor H cause atypical hemolytic uremic syndrome - Warwicker P et al. Kidney Int. 
1998;53:836–44. 
* 1998: Molecular basis of cystinosis - Town M et al. Nat Genet. 1998;18:319-24. 
* 1999: Mutations in a paracellular protein (claudin-16) cause familial hypomagnesemia with 
hypercalciuria - Simon DB et al. Science. 1999;285:103-6. 
* 2000: Podocin (NPHS2) is the major gene for steroid-resistant nephrotic syndrome - Boute et al. Nat 
Genet 24: 349-354, 2000. 
 
* 2001: Mutations in different genes cause Bardet Biedl syndrome (digenic inheritance) - Katsanis et al. 
Science 293: 2256-2259, 2001.  
 
* 2001: Mutations in WNK kinases alter the regulation of sodium, potassium and blood pressure - Wilson 
FH, et al. Science. 2001;293:1107-12. 
 
*2002: Mutations in uromodulin (Tamm-Horsfall protein) cause familial juvenile hyperuricemic 
nephropathy, an autosomal dominant form of interstitial nephritis - Hart TC, et al.  J Med Genet. 
2002;39:882-92. 
 
*2005: Mutations in a cation channel (TRPC6) causes glomerular disease - Winn MP et al. Science. 
2005;308:1801-4.  
 
*2010: First success of exome sequencing in rare renal disease:SDCCA8 in Senior Loken syndrome 
(retinal-renal ciliopathy) - Otto et al, Nat Genet. 2010;42:840-50. 
*2011: Broadening spectrum of HNF1beta gene mutations - Faguer S et al . Kidney Int. 2011;80:768-76. 
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*2013: Description of MUC1 as the cause of medullary cystic kidney disease type 1 (MCKD1). The gene 
was missed by massively parallel sequencing, evidencing the need for refinement of analysis methods 
and assessment of clinical utility of whole exome sequencing for autosomal dominant heterogeneous 
conditions - Kirby A et al. Nat Genet 45: 299-303, 2013. 
Milestones in treatment: 
*1981: Oral cysteamine for cystinosis - Yudkoff M et al. N Engl J Med. 1981;304:141-5. 
*2000: Enzyme replacement therapy for Fabry disease - Schiffmann R, et al. Proc Natl Acad Sci U S A. 
2000;97:365-70; Schiffmann R, et al. JAMA. 2001 Jun 6;285(21):2743-9. 
*2000: First in-vitro evidence that pharmacological chaperones can rescue cell-surface expression and 
function of misfolded vasopressin type-2 receptors in nephrogenic diabetes insipidus - Morello et al, J 
Clin Invest. 2000; 105:887-95. 
*2008: Development of mTOR inhibitors for tuberous sclerosis -  Bissler JJ et al. N Engl J Med 
2008;358:140-151. 
*2009: Eculizumab for atypical hemolytic uremic syndrome - Nürnberger J, et al. N Engl J Med. 
2009;360:542-4. Gruppo RA, Rother RP. N Engl J Med. 2009;360:544-6. 
*2012: First positive, randomized controlled trial for ADPKD - Torres VE et al. N Engl J Med. 
2012;367:2407-18. 
 
Note: The original references of the milestones are available in the Supplementary Material. 
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Table 2. List and classification of inherited kidney disorders.  
 
 Trans 
mission 
Defective protein Protein function OMIM 
entry 
I. Genetic disorders of renal growth and structure      
 Congenital abnormalities of the kidney and urinary 
tract 
    
 Renal adysplasia AR 
AR 
AR 
Ret  
Pax2  
Uroplakin-3α 
Tyrosine kinase receptor 
Transcription factor 
Membrane protein 
191830 
 Vesicoureteral reflux AD Tenascin-XB extracellular matrix glycoprotein  
 Renal coloboma syndrome AD Pax2 Transcription factor 120330 
 Renal cysts and diabetes syndrome AD HNF1ß Transcription factor 137920 
 Branchio-oto-renal syndrome AD 
AD 
Eya1  
Six5 
Transcription factor  
Transcription factor 
113650 
 Fraser syndrome AR 
AR 
AR 
Fras1  
Grip1  
Frem2 
Extracellular matrix protein  
Receptor interacting protein 
Extracellular matrix protein 
219000 
 Urofacial (Ochoa) syndrome AR 
AR 
Heparanase-2 (HPA2)  
Lrig2 
Matrix enzyme 
Membrane protein 
236730 
615112  
     Hypoparathyroidism, deafness, renal disease 
syndrome 
AD GATA3 Transcription factor 146255 
 Kallmann syndrome XL 
AR 
Anosmin1 
FGFR1 
Adhesion-like protein, protease inhibitor 
 Tyrosine kinase receptor 
308700 
147950 
 Split-hand/split-foot malformation AD (dupl.10q24) - 246560  
 Townes-Brocks syndrome AD SALL1 Transcription factor 602218 
 Perlman syndrome (nephroblastomatosis, 
gigantism) 
AR DIS3L2 Ribonuclease 267000 
 Renal tubular dysgenesis AR 
AR 
AR 
AR 
Renin  
Angiotensinogen  
AT1 receptor  
ACE 
Endopeptidase (angiotensinogenase) 
Secreted peptide 
G-protein coupled receptor 
Carboxypeptidase 
267430 
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Ciliopathies     
 Autosomal dominant polycystic kidney disease, 
            types 1 and 2 
AD 
AD 
Polycystin-1 
polycystin-2 
Ciliary protein, regulates cilium length 
Ciliary protein, regulates cilium length 
173900  
613095 
 Autosomal recessive polycystic kidney disease AR Fibrocystin Receptor-like cilium/cytoskeleton protein (centrosome regulator) 263200 
 Medullary cystic kidney disease/ 
          familial juvenile hyperuricemic nephropathy 
AD 
AD 
AD 
MUC1  
Uromodulin  
Renin 
Surface glycoprotein with adhesive and anti-adhesive properties 
Surface-bound and secreted glycoprotein  
Endopeptidase (angiotensinogenase) 
174000 
603860  
613092 
 Nephronophthisis 
            type 1   (= Joubert 4) 
            type 2  
            type 3  (= Renal-hepatic-pancreatic S. 1) 
            type 4 
            type 5 
            type 6   (= Joubert 5,  Meckel 4) 
            type 7 
            type 8   (= Joubert 7, Meckel 5) 
            type 9 
            type 10 (= Senior-Loken 7) 
            type 11 (= (Joubert 6, Meckel 3) 
            type 12 (= Joubert 11) 
            type 13 (= Cranioectodermal dysplasia 4) 
            type 14 (= Joubert 19) 
            type 15 
            type 16 
 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
 
Nephrocystin-1 
Inversin  
Nephrocystin-3  
Nephrocystin-4 
IQCB-1 (Nephrocystin-5)  
CEP290 (Nephrocystin-6)  
GLIS2  
RPGRIP1L (Nephrocystin-8) 
NEK8 (Nephrocystin-9) 
SDCCAG8 (Nephrocystin-10)  
TMEM67 (Meckelin) 
TTC21B  
WDR19 
ZNF423 
CEP164  
ANKS6 
 
Ciliary protein, involved in organiation of apical junctions 
Ciliary protein, associates with microtubules, inhibits WNT signaling 
Ciliary protein, inhibits WNT signaling 
Ciliary protein, invovlved in organiation of apical junctions 
Centrosome protein, Involved in ciliogenesis 
Centrosome protein, involved in ciliogenesis  
Transcription factor  
Centrosome protein, regulates TXA2 receptor signaling 
Ser/thr-protein kinase, targets proteins to cilia 
Centrosome-associated protein, may be involved in ciliogenesis 
Ciliary protein, involved in centrosome migration 
Ciliary protein, involved in retrograde ciliary transport 
Ciliary protein, involved in retrograde ciliary transport 
Centrosome protein, involved in DNA damage response  
Centrosome protein, involved in DNA damage response 
Ciliary protein 
 
256100 
602088  
604387  
606966  
609254  
610188  
611498 
611560  
613824 
613615  
613550  
613820  
614377  
614844  
614845  
615382 
    Joubert syndrome (only subtypes with renal 
phenotype)   
           type 1 
           type 2 
           type 4 
           type 5 
           type 6 
           type 7 
           type 9 
           type 10 
 
AR  
AR 
AR 
AR 
AR 
AR 
AR 
XLR  
AR 
 
INPP5E 
TMEM216  
NPHP1 (Nephrocystin-1)  
CEP290 (Nephrocystin-6) 
TMEM67 (Meckelin)  
RPGRIP1L (Nephrocystin-8)  
CC2D2A  
OFD1  
TTC21B  
 
IP3 phosphatase 
Ciliary protein, may be involved in ciliogenesis 
Ciliary protein, involved in organiation of apical junctions  
Centrosome protein, involved in ciliogenesis  
Ciliary protein, involved in centrosome migration  
Centrosome protein, regulates TXA2 receptor signaling  
Ciliary protein, involved in ciliogenesis and SHH signaling 
Centrosome protein, involved in ciliogenesis  
Ciliary protein, involved in retrograde ciliary transport  
 
213300 
608091 
609583 
610188 
610688 
611560 
612285 
300804 
613820 
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           type 11 
           type 14 
           type 15 
           type 16 
           type 18 
           type 19 
           type 20 
AR 
AR 
AR 
AR 
AR 
AR 
TMEM237  
CEP41  
TMEM138  
TCTN3  
ZNF423  
TMEM231 
Ciliary protein, involved in ciliogenesis  
Centrosome protein, required during ciliogenesis 
Multi-pass transmembrane protein required for ciliogenesis 
Membrane protein, required for ciliogenesis and SHH signaling  
Centrosome protein, involved in DNA damage response  
Ciliary protein, required for ciliogenesis and SHH signaling  
614424 
614464 
614465 
614815 
614844  
 Meckel-Gruber syndrome  
           type 1 
           type 2 
           type 3 
           type 4 
 
AR 
AR 
AR 
AR 
 
MKS1  
TMEM216  
TMEM67 (Meckelin)  
CEP290 (Nephrocystin-6) 
 
Ciliary protein, regulates cilia structure and function 
Ciliary protein, may be involved in ciliogenesis) 
Ciliary protein, involved in centrosome migration 
Centrosome protein, involved in ciliogenesis 
 
209900  
603194  
607361  
611134 
 Short rib-polydactyly syndrome (Jeune S.) 
           type 1 
           type 2 
           type 3 
           type 4 
           type 5 
           type 6 
 
AR 
AR 
AR 
AR 
AR 
AR 
 
unknown 
NEK1 
Dynein  
unknown 
WDR35 
WDR60 
 
- 
Centrosomal Ser/Thr protein kinase, involved in ciliogenesis  
Ciliary protein, involved in retrograde ciliary transport 
- 
Ciliary protein, involved in retrograde ciliary transport 
Cilium base protein, involved in ciliogenesis 
 
263530  
263520 
263510  
269860 
614091  
615503 
 Bardet-Biedl syndrome 
           type 1 
           type 2 
           type 3 
           type 4 
           type 5 
           type 6 
           type 7 
           type 8 
           type 9 
           type 10 
           type 11 
           type 12 
           type 13 
           type 14 
           type 15 
 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
AR 
  
BBS1 
BBS2 
ARL6 
BBS4 
BBS5  
MKKS 
BBS7 
TTC8 
PTHB1 
BBS10 
TRIM32 
BBS12 
MKS1  
CEP290 
Human fritz (C2orf86) 
  
BBSome complex protein, required for ciliogenesis 
BBSome complex protein, required for ciliogenesis 
Cilium base protein, targets BBSome to plasma membrane 
BBSome complex protein, required for ciliogenesis 
BBSome complex protein, required for ciliogenesis 
Chaperone, may assist folding of BBSome proteins 
BBSome complex protein, required for ciliogenesis 
BBSome complex protein, required for ciliogenesis 
BBSome complex protein, required for ciliogenesis 
Chaperone, affects folding/ stability of ciliary/basal body proteins 
E3 ubiquitin ligase activity 
Chaperone, assists folding of BBSome proteins 
Ciliary protein, regulates cilia structure and function 
Centrosome protein, involved in ciliogenesis 
Controls ciliogenesis by regulating septin cytoskeleton 
 
209900 
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 Alström syndrome AR ALMS1 Centrosome protein, required for cilia formation/maintenance 203800 
 Cranioectodermal dysplasia, types 1-4 
          (Sensenbrenner syndrome) 
AR IFT122  
WDR35  
IFT43  
WDR19  
Ciliary protein, involved in retrograde ciliary transport 
Ciliary protein, involved in retrograde ciliary transport  
Ciliary protein, involved in retrograde ciliary transport  
Ciliary protein, involved in retrograde ciliary transport 
218330  
613610  
614099  
614378 
 Oral-facial-digital syndrome type 1 XLD OFD1 Centrosome protein, involved in ciliogenesis 311200 
 Renal-hepatic-pancreatic dysplasia  
           (Ivemark syndrome) 
AR Nephrocystin-3 
NEK8 (nephrocystin-9) 
Ciliary protein, inhibits WNT signaling 
Ser/Thr protein kinase, may target proteins to cilia 
208540 
615415 
II. Genetic disorders of renal function     
  Glomerular diseases     
 Autosomal recessive SRNS  
           
AR Nephrin  
podocin  
PLCE1 
MYO1E  
PTPRO  
Diacyl glyerol kinase-ε  
ARHGDIA 
ARHGAP24  
Podocyte adhesion receptor, component of slit diaphragm 
Podocyte membrane protein, links slit diaphragm to cytoskeleton  
Phospholipase, regulates PKC pathway and small GTPases 
Cytoplasmic protein, regulates actin cytoskeleton functions 
Receptor-type tyrosine phosphatase  
Enzyme involved in cell signaling, activates PKC pathway  
Cytoplasmic protein, involved in Rho protein signaling  
Rho GTPase-activating protein  
256300 
600995  
610725  
614196  
614455  
601440  
615244 
 Autosomal dominant SRNS          AD WT1 
Inverted formin-2 (INF2)  
α-actinin-4 (ACTN4)  
TRPC6 
Transcription factor  
Cytoplasmic protein, severs actin filaments  
F-actin cross-linking cytoplasmic protein 
Receptor-activated calcium channel 
256370 
613237 
603278  
603965 
 Denys-Drash syndrome, Frasier syndrome AD WT1 Transcription factor 194080  
136680 
 WAGR syndrome AD WT1 / Pax6 Transcription factors 194072 
 Pierson syndrome AR Laminin-ß2 Extracellular matrix glycoprotein 609049 
 Nail-Patella syndrome AD LMX1B Transcription factor 161200 
 Schimke immuno-osseous dystrophy AR SMARCAL1 Annealing helicase, catalyzes rewinding of unwound DNA  
 Mitochondrial disorders with SRNS:  
              Primary CoQ10 deficiency, types 1 and 6 
 
AR 
 
COQ2 
COQ6 
ADCK4 
 
Enzyme involved in COQ10  biosynthesis 
Enzyme involved in COQ10  biosynthesis 
Mitochondrial protein involved in CoQ10 biosynthesis 
 
607426 
614650 
 Fabry disease XL alpha-galactosidase A Lysosomal enzyme, catalyzes galactosyl-glycolipid moieties 301500 
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 Alport syndrome XL 
AR 
Collagen IV α-5,  
Collagen IV α-4, 
Collagen IV α-3 
α5-chain of type IV collagen  
α4-chain of type IV collagen  
α3-chain of type IV collagen 
301050 
203780 
 Benign familial hematuria  
         (thin basement membane nephropathy) 
AD Collagen IV α-3 α3-chain of type IV collagen 141200 
 Fechtner syndrome  
          (Alport syndrome with macrothrombocytopenia) 
AD MYH9 Non-muscle myosin, inolved in cell shape and movement 153640 
 Alport syndrome with leiomyomatosis XL Collagen IV alpha-5  
+ Collagen IV α-6 
α5- and α6-chains of type IV collagen 308940 
 Familial amyloidosis AD Fibrinogen A-α  
lysozyme 
APOA1  
ß2-microglobulin 
Secreted protein  
Secreted enzyme  
Secreted lipoprotein  
Secreted protein 
105200 
Renal tubular diseases and metabolic diseases     
 Renal glucosuria AR/AD SLC5A2 Sodium/glucose cotransporter 233100 
 Dicarboylic aminoaciduria AR SLC1A1 Glutamate transporter 222730 
 Lysinuric protein intolerance AR SLC7A7 Cationic Amino Acid Transporter 222700 
 Proximal renal tubular acidosis AR SLC4A4 Sodium bicarbonate cotransporter 604278 
 Distal renal tubular acidosis AD SLC4A1 Inorganic anion transmembrane transport protein 179800 
 Renal tubular acidosis with osteopetrosis AR Carbonic anhydrase II Enzyme involved in bicarbonate transport 611492 
 Hypophosphatemic rickets XL PHEX Endopeptidase, degrades FGF23 307800 
  AD FGF23 Osteocyte hormone, inhibits tubular phosphate reabsorption 193100 
  AR 
AR 
ENPP1 
DMP1 
Pyrophosphatase, regulates mineralization 
Osteoblast transcriptional activator/osteocyte matrix regulator 
613312 
 Nephropathic cystinosis  Cystinosin (CTNS) Lysosomal membrane cystine transporter 606272 
 Primary Fanconi syndrome types 1 and 2 AD 
AR 
15q15.3 
SLC34A1(NaPi3) 
Affected gene(s) unknown 
Sodium/phosphate cotransporter 
134600 
182309 
 Fanconi-Bickel syndrome (hepatorenal 
glycogenosis) 
AR SLC2A2(GLUT2) Facilitated glucose transporter 227810 
Dent disease, type 1 
Dent disease, type 2  
Lowe oculocrebrorenal syndrome 
XL 
XL 
XL 
ClC-5 
Inositol polyphosphate 5-
phosphatase (OCRL1) 
Chloride-proton exchanger 
5-phosphatase, regulates early endosomes 
300009 
300535 
309000 
Hereditary renal hypouricemia AR URAT1 (SLC22A12) Urate transporter 220150 
 Bartter syndrome types 1-4 AR SLC12A1  Sodium-potassium-chloride cotransporter 601678  
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KCNJ1  
CLCNKB  
CLNCKA  
BSND (Barttin) 
Potassium channel 
Chloride channel 
Chloride channel 
ß-subunit of CLCNKA and CLCNKB chloride channels 
241200  
607364  
 
602522 
Familial juvenile hyperuricemic nephropathy 
Medullary cystic kidney disease type 2 
AD Uromodulin (Tamm-Horsfall 
protein) 
Secretory protein 162000 
603860 
Familial hypocalciuric hypercalcemia type 1 
Neonatal severe hyperparathyroidism 
Autosomal dominant hypocalcemia (incl. with 
Bartter syndrome 
AD 
AR 
AD 
CASR 
CASR 
CASR 
Calcium-sensing receptor (loss of function) 
Calcium-sensing receptor (loss of function) 
Calcium-sensing receptor (gain of function) 
145980 
239200 
601198 
 Gitelman syndrome AR SLC12A3 Thiazide-sensitive sodium/chloride cotransporter 263800 
Hypomagnesemia (intestinal, type 1) with 
secondary hypocalcemia 
Hypomagnesemia (renal, type 2) 
Hypomagnesemia (renal, type 3) 
Hypomagnesemia (renal, type 4) 
Hypomagnesemia (renal, type 5) with 
hypercalcinuria, nephrocalcinosis and ocular 
involvement 
Hypomagnesemia (renal, type 6) 
AR 
 
AD 
AR 
AR 
AR 
 
 
AD 
TRPM6 
 
FXYD2 
Claudin 16 
EGF 
Claudin 19 
 
 
Cyclin-M2 
Magnesium channel 
 
Gamma subunit of sodium-potassium-ATPase 
Paracellular protein, component of tight junctions 
Epidermal growth factor 
Paracellular protein, component of tight junctions 
 
 
Membrane protein of unknown function 
602014 
 
154020 
248250 
611718 
248190 
 
 
613882 
 Liddle syndrome AD SCNN1G,  
SCNN1B 
γ-subunit of amiloride-sensitive sodium channel (gain of function) 
ß-subunit of amiloride-sensitive sodium channel (gain of function) 
177200 
 Pseudohypoaldosteronism type 1 AR SCNN1A  
SCNN1G 
SCNN1B 
α-subunit of amiloride-sensitive sodium channel  
γ-subunit of amiloride-sensitive sodium channel  
ß-subunit of amiloride-sensitive sodium channel 
264350 
 Pseudohypoaldosteronism type 2 
          (Gordon syndrome) 
AD WNK1  
WNK4  
KLHL3  
Cullin-3 
Ser/thr kinase modulating Na- and K-coupled Cl transporters  
Ser/thr kinase modulating Na- and K-coupled Cl transporters 
Structural protein mediating ubiquitination of SLC12A3 
Component of ubiquitin E3 ligase complex 
145260 
 SeSAME syndrome (EAST syndrome) AR KCNJ10 Potassium channel  612780 
Distal renal tubular acidosis 
Distal renal tubular acidosis, with hemolytic 
anemia 
Distal renal tubular acidosis, with progressive 
nerve deafness 
AR 
AR 
 
AR 
ATP6V0A4 
SLC4A1 
 
ATP6V1B1 
Subunit of the vacuolar proton ATPase 
Anion exchanger (Erythroid band 3) 
 
Subunit of the vacuolar proton ATPase 
602722 
611590 
 
267300 
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 Nephrogenic diabetes insipidus type 1 
 
Nephrogenic syndrome of inappropriate 
antidiuresis 
XL 
 
XL 
Vasopressin V2 receptor 
 
Vasopressin V2 receptor  
G-protein coupled receptor for arginine vasopressin (loss of 
function) 
G-protein coupled receptor for arginine vasopressin (gain of 
function) 
304800 
 
300539 
 Nephrogenic diabetes insipidus type 2 AD/AR Aquaporin 2 Water channel 125800 
Nephrolithiasis     
 Cystinuria AD 
AR 
SLC3A1 
SLC7A9 
Activator of cystine transporter  SLC7A9 
Cystine transporter 
220100 
         Dent disease type 1 
Dent disease type 2 
Lowe oculocerebrorenal syndrome 
XL 
XL 
XL 
ClC-5 
Inositol polyphosphate 5-
phosphatase (OCRL1) 
Chloride-proton exchanger 
5-phosphatase, regulates early endosomes 
300009 
300535 
309000 
         Primary hyperoxaluria type I AR Alanine-glyoxylate 
aminotransferase 
Vitamin B6-dependent peroxisomal enzyme 259900 
         Primary hyperoxaluria type II AR Glyoxylate reductase/ 
hydroxypyruvate reductase 
Peroxisomal enzyme  260000 
         Primary hyperoxaluria type III AR 4-hydroxy-2-oxoglutarate 
aldolase (HOGA1) 
Mitochondrial enzyme (hydroxyproline metabolic pathway) 613616 
 Adenine-phosphoribosyl-transferase deficiency AR Adenine phosphoribosyl-
transferase (APRT) 
Cytoplasmic enzyme forming AMP from adenine 614723 
 Xanthinuria type 1 AR Xanthine dehydrogenase Key enzye in purine degradation 278300 
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Table 3. Examples of European and international networks focusing on rare inherited kidney diseases. 
 EPIRARE: European Platform for Rare Disease Registries (www.epirare.eu) 
 PARENT: Patient Registries Initiative (www.patientregistries.eu) 
 RD-CONNECT: An integrated platform connecting databases, registries, biobanks and clinical 
bioinformatics for rare disease research (www.rd-connect.eu)   
 IRDiRC: International Rare Diseases Research Consortium (www.irdic.org) 
 EURenOmics: EURenOmics integrates a large number of registries and biobanks with detailed 
phenotype information and biomaterials from cumulatively more than 13,000 patients 
(www.eurenomics.eu) 
 ERA-EDTA WGIKD: Working Group on Inherited Kidney Diseases (http://www.era-
edta.org/wgikd/ERA-EDTA_working_group_on_Inherited_kidney_disorders.htm)  
 NORD: National Organization for Rare Disorders (www.rarediseases.org) 
 ORPHANET: The portal for rare diseases and orphan drugs (www.orpha.net) 
 EURORDIS: The European Organization for Rare Diseases (www.eurordis.org) 
 EMA and orphan designation: European Medicines Agency (www.ema.europa.eu) 
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Figure 1: Inherited kidney disorders linked to nephron segments. 
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Figure 2: Application of -omics technologies in rare kidney diseases. 
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Figure 3: Exemples of molecular targets in rare kidney disorders. 
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c. Complement activation in atypical hemolytic uremic syndrome 
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